drugset
drugset / Trial / NCT05686642

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

NCT05686642 ↗

Phase 2 Recruiting 300 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

Timeline

Start
2023-04-06
Primary completion
2026-12-10
Completion
2026-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LT3001 Unknown — Intravenous

Indications

ischemic stroke